1. Market Research
  2. > Wilex AG – Product Pipeline Review – 2013

Wilex AG – Product Pipeline Review – 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 71 pages

Wilex AG – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Wilex AG - Product Pipeline Review - 2013” provides data on the Wilex AG’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Wilex AG’s corporate website, SEC filings, investor presentations and featured press releases, both from Wilex AG and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Wilex AG - Brief Wilex AG overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Wilex AG human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Wilex AG with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Wilex AG’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Wilex AG’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Wilex AG in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Wilex AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Wilex AG.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Wilex AG and identify potential opportunities in those areas.

Table Of Contents

Wilex AG - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Wilex AG Snapshot 6
Wilex AG Overview 6
Key Information 6
Key Facts 6
Wilex AG - Research and Development Overview 7
Key Therapeutic Areas 7
Wilex AG - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Wilex AG - Pipeline Products Glance 11
Wilex AG - Late Stage Pipeline 11
Phase III Products/Combination Treatment Modalities 11
Wilex AG Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Wilex AG - Early Stage Pipeline Products 14
Pre-Clinical Products/Combination Treatment Modalities 14
Wilex AG - Drug Profiles 15
ADC Platform 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
Antibody Program For Cancer 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
girentuximab 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
upamostat 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
WX-037 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
WX-UK1 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Wilex AG - Pipeline Analysis 23
Wilex AG - Pipeline Products by Therapeutic Class 23
Wilex AG - Pipeline Products by Route of Administration 24
Wilex AG - Pipeline Products By Mechanism of Action 25
Wilex AG - Recent Pipeline Updates 27
Wilex AG - Dormant Projects 30
Wilex AG - Company Statement 31
Wilex AG - Locations And Subsidiaries 33
Head Office 33
Other Locations and Subsidiaries 33
Wilex AG, Recent Developments 34
Wilex AG- Press Release 34
Jun 07, 2010: WILEX Presents Positive Final Phase II Data Of Mesupron At ASCO For The Treatment Of Pancreatic Cancer 34
May 18, 2010: WILEX Announces Final Results From Phase III Trial Of REDECTANE 35
May 03, 2010: Final Phase II Data Of WILEX's MESUPRON Confirm Impressive Increase In Overall Survival Of Patients With Pancreatic Cancer 35
May 03, 2010: Wilex AG Announces Final Phase II Data Of Mesupron, Confirming Impressive Increase In Overall Survival Of Patients With Pancreatic Cancer 36
Financial Deals Landscape 38
Wilex AG, Deals Summary 38
Wilex AG, Pharmaceuticals and Healthcare, Deal Details 39
Asset Transactions 39
Wilex Acquires Oncogene Science Assets From Siemens Healthcare Diagnostics 39
Wilex Acquires Intellectual Property From Dendreon 41
Partnerships 43
WILEX Enters Into Licensing Agreement With Ion Beam Applications 43
Wilex And Nuclea Biotechnologies Enter Into Agreement For Serum HER-2/Neu ELISA Test 45
Wilex Enters Into Co-Marketing Agreement With Immuno-Biological Labs For Portfolio Of Biomarker Tests 46
Wilex Enters Into Distribution Agreement With GeneDiagnostics For Serum HER-2/neu Test 48
WILEX Enters Into Co-Marketing Agreement With ALPCO Diagnostics 49
Licensing Agreements 51
WILEX Enters Into Licensing Agreement With Prometheus Labs For RENCAREX 51
UCB Enters Into Licensing Agreement With WILEX 53
Equity Offering 55
Wilex Completes Private Placement Of Shares For $12.4 Million 55
Wilex Completes Rights Offering Of Shares For $7.8 Million 57
Wilex Completes Rights Offering Of Shares For $12.6 Million 58
WILEX Enters Into Standby Equity Distribution Agreement For $27 Million 60
WILEX Completes Rights Issue Of Common Stock For $13.4 Million 62
Acquisition 64
WILEX Acquires Heidelberg Pharma For $26.8 Million 64
dievini Hopp BioTech Holding Acquires 0.12% Stake In WILEX 66
UCB Pharma Acquires An Additional 6.65% Stake In WILEX 68
Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 71
Disclaimer 71



List of Tables

Wilex AG, Key Information 6
Wilex AG, Key Facts 6
Wilex AG - Pipeline by Indication, 2013 8
Wilex AG - Pipeline by Stage of Development, 2013 9
Wilex AG - Monotherapy Products in Pipeline, 2013 10
Wilex AG - Phase III, 2013 11
Wilex AG - Phase II, 2013 12
Wilex AG - Phase I, 2013 13
Wilex AG - Pre-Clinical, 2013 14
Wilex AG - Pipeline By Therapeutic Class, 2013 23
Wilex AG - Pipeline By Route of Administration, 2013 24
Wilex AG - Pipeline Products By Mechanism of Action, 2013 26
Wilex AG - Recent Pipeline Updates, 2013 27
Wilex AG - Dormant Developmental Projects,2013 30
Wilex AG, Subsidiaries 33
Wilex AG, Deals Summary 38
Wilex Acquires Oncogene Science Assets From Siemens Healthcare Diagnostics 39
Wilex Acquires Intellectual Property From Dendreon 41
WILEX Enters Into Licensing Agreement With Ion Beam Applications 43
Wilex And Nuclea Biotechnologies Enter Into Agreement For Serum HER-2/Neu ELISA Test 45
Wilex Enters Into Co-Marketing Agreement With Immuno-Biological Labs For Portfolio Of Biomarker Tests 46
Wilex Enters Into Distribution Agreement With GeneDiagnostics For Serum HER-2/neu Test 48
WILEX Enters Into Co-Marketing Agreement With ALPCO Diagnostics 49
WILEX Enters Into Licensing Agreement With Prometheus Labs For RENCAREX 51
UCB Enters Into Licensing Agreement With WILEX 53
Wilex Completes Private Placement Of Shares For $12.4 Million 55
Wilex Completes Rights Offering Of Shares For $7.8 Million 57
Wilex Completes Rights Offering Of Shares For $12.6 Million 58
WILEX Enters Into Standby Equity Distribution Agreement For $27 Million 60
WILEX Completes Rights Issue Of Common Stock For $13.4 Million 62
WILEX Acquires Heidelberg Pharma For $26.8 Million 64
dievini Hopp BioTech Holding Acquires 0.12% Stake In WILEX 66
UCB Pharma Acquires An Additional 6.65% Stake In WILEX 68



List of Figures

Wilex AG - Pipeline by Indication, 2013 8
Wilex AG - Pipeline by Stage of Development, 2013 9
Wilex AG - Monotherapy Products in Pipeline, 2013 10
Wilex AG - Pipeline By Route of Administration, 2013 24
Wilex AG - Pipeline Products By Mechanism of Action, 2013 25

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.